Publications & references

Publications: Peer-reviewed papers with Peregrion employees as (co)author
References: Peer-reviewed papers with references to our work

All Types
Publication(13)
Reference(6)

Absorption, metabolism, and excretion of single dose oral [14C]camizestrant in healthy human female participants

Sykes et. al. (AstraZeneca) · 2026

Absolute Bioavailability and Absorption, Distribution, Metabolism, and Excretion of [14C]Xevinapant, a Potent, Oral, Small-Molecule IAP Inhibitor

Menetrey et. al. (Debiopharm) · 2026

A Phase 1 Microtracer Study Evaluating the MassBalance, Excretion, and Pharmacokinetics of Osivelotor inHealthy Participants

Zimmerman et. al. (Pfizer) · 2026

Anabolic Effects of Salbutamol Are Lost Upon Immobilization

de Jong et. al. (TNO) · 2025

Mass balance, pharmacokinetics, metabolism, and excretion of radiolabeled acoziborole, a potential novel treatment for human African trypanosomiasis, following single microtracer oral dose to humans

Chillon et. al. (DNDi) · 2025

Microtracer‐Based Assessment of the Mass Balance, Pharmacokinetics, and Excretion of [14C]Berzosertib, an Intravenous ATR Inhibitor, in Patients With Advanced Solid Tumors: A Phase 1 Study

Bolleddula et. al. (Merck KGaA) · 2025

The Pharmacokinetics, Metabolism, and Clearance Mechanisms of Ritlecitinib, a Janus Kinase 3 and Tyrosine-Protein Kinase Family Inhibitor, in Humans

Bauman et. al. (Pfizer) · 2024

Mass Balance and Metabolite Profile after Single and Multiple Oral Doses of Pritelivir in Healthy Subjects

Bonsmann et. al. (AiCuris) · 2024

Absorption, Metabolism, and Excretion of 14C-Emvododstat Following Repeat Daily Oral Dose Administration in Human Volunteers Using a Combination of Microtracer Radioactivity and High-Radioactivity Doses

Ma et. al. (PTC Therapeutics) · 2024

The Metabolism of Lufotrelvir, a Prodrug Investigated for the Treatment of SARS-COV2 in Humans Following Intravenous Administration

Cheruvu et. al. (Pfizer) · 2023

Mass Balance and Absorption, Distribution, Metabolism, and Excretion Properties of Balcinrenone following Oral Administration in Combination with Intravenous Microtracer in Healthy Subjects

Lindmark et. al. (AstraZeneca) · 2023

Application of Accelerator Mass Spectrometry to Characterize the Mass Balance Recovery and Disposition of AZD4831, a Novel Myeloperoxidase Inhibitor, following Administration of an Oral Radiolabeled Microtracer Dose in Humans

Bhattacharya et. al. (AstraZeneca) · 2023

Microdosing as a Potential Tool to Enhance Clinical Development of Novel Antibiotics: A Tissue and Plasma PK Feasibility Study with Ciprofloxacin

Oesterreicher et. al. (Medical University of Vienna) · 2022

Characterization of Clinical Absorption, Distribution, Metabolism, and Excretion and Pharmacokinetics of Velsecorat Using an Intravenous Microtracer Combined with an Inhaled Dose in Healthy Subjects

Holmberg et. al. (AstraZeneca) · 2022

Quantification of azacitidine incorporation into human DNA/RNA by accelerator mass spectrometry as direct measure of target engagement

Wang et. al. (BMS) · 2021

The impact of early human data on clinical development: there is time to win

Swart et. al. (Novartis) · 2016

To Apply Microdosing or Not? Recommendations to Single Out Compounds with Non-Linear Pharmacokinetics

Bosgra et. al. (TNO) · 2016

Microdosing of a Carbon-14 Labeled Protein in Healthy Volunteers Accurately Predicts Its Pharmacokinetics at Therapeutic Dosages

Vlaming et. al. (TNO/AMRIF) · 2015

Automated combustion accelerator mass spectrometry for the analysis of biomedical samples in the low attomole range

van Duijn et. al. (TNO) · 2014